Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo, Toshiyuki Sumi, Takayuki Kaburagi, Kenichiro Ito, Yasuyuki Ikezawa, Keiki Yokoo, Hajime Kikuchi, Sayaka Kudo, Masami Yamazoe, Ryota Shigaki, Keita Tagami, Toshiyuki Tenma, Tatsuru Ishikawa, Mamoru Takahashi, Takaaki Sasaki, Hajime Asahina, S · 2026
Read Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes by Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo, Toshiyuki Sumi, Takayuki Kaburagi, Kenichiro Ito, Yasuyuki Ikezawa, Keiki Yokoo, Hajime Kikuchi, Sayaka Kudo, Masami Yamazoe, Ryota Shigaki, Keita Tagami, Toshiyuki Tenma, Tatsuru Ishikawa, Mamoru Takahashi, Takaaki Sasaki, Hajime Asahina, S (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13394325.txt.
Description
Yutaro Nagano and others weigh afatinib against osimertinib for lung cancers with rare EGFR gene changes in a 2026 real-world study. These mixed tumors leave the best first drug unsure, as does the later role of drugs that wake the body's defenses.
The study spanned 29 Japan hospitals and 162 people with late non-squamous lung cancer. Rare gene changes counted, but exon 20 inserts and new T790M were left out, and first drugs ran from 2015 to 2024. Weighting evened out start gaps, and later drug paths were tracked. Cancer doctors gain head-to-head results for a group oft left out of big trials.
Catalog record
| CREATOR | Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo, Toshiyuki Sumi, Takayuki Kaburagi, Kenichiro Ito, Yasuyuki Ikezawa, Keiki Yokoo, Hajime Kikuchi, Sayaka Kudo, Masami Yamazoe, Ryota Shigaki, Keita Tagami, Toshiyuki Tenma, Tatsuru Ishikawa, Mamoru Takahashi, Takaaki Sasaki, Hajime Asahina, S |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |